StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Gyre Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -14.4%. For fiscal 2025 it was 9.9%, against 15.3% the year before. The highest annual figure on record is 15.3% in fiscal 2010.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 20259.9%−5.4
FY2024Dec 31, 202415.3%+74.5
FY2023Dec 31, 2023-59.3%−68.3
FY2022Dec 31, 20229.0%+1206.8
FY2021Dec 31, 2021-1197.8%−923.9
FY2020Dec 31, 2020-273.9%+563426.1
FY2018Dec 31, 2018-563700.0%−561556.4
FY2017Dec 31, 2017-2143.6%+586.9
FY2014Dec 31, 2014-2730.5%−2451.7
FY2013Dec 31, 2013-278.9%−264.8
FY2012Dec 31, 2012-14.1%−4.1
FY2011Dec 31, 2011-10.0%−25.3
FY2010Dec 31, 201015.3%+176.2
FY2009Dec 31, 2009-160.9%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-4.6%−9.2
Q2 FY2026Jun 30, 2026-49.3%−41.8
Q1 FY2026Mar 31, 2026-41.5%−51.8
Q4 FY2025Dec 31, 202541.1%+38.7
Q3 FY2025Sep 30, 20254.6%−12.0
Q2 FY2025Jun 30, 2025-7.5%−20.2
Q1 FY2025Mar 31, 202510.3%−19.4
Q4 FY2024Dec 31, 20242.4%+339.9
Q3 FY2024Sep 30, 202416.6%−23.2
Q2 FY2024Jun 30, 202412.7%−4.3
Q1 FY2024Mar 31, 202429.7%+3.0
Q4 FY2023Dec 31, 2023-337.5%+1514.0
Q3 FY2023Sep 30, 202339.8%+872.3
Q2 FY2023Jun 30, 202317.0%+1114.3
Q1 FY2023Mar 31, 202326.7%+1785.9
Q1 FY2022Mar 31, 2022-1851.5%−322.0
Q4 FY2021Dec 31, 2021-832.5%+95.2
Q3 FY2021Sep 30, 2021-1097.4%+705.5
Q2 FY2021Jun 30, 2021-1759.2%−712.1
Q1 FY2021Mar 31, 2021-1529.5%−1498.5
Q4 FY2020Dec 31, 2020-927.7%+110389.0
Q3 FY2020Sep 30, 2020-1802.9%+30.1
Q2 FY2020Jun 30, 2020-1047.1%+801.3
Q1 FY2020Mar 31, 2020-31.0%+5324.0
Q1 FY2018Mar 31, 2018-111316.7%–
Q4 FY2017Dec 31, 2017-1833.0%–
Q3 FY2017Sep 30, 2017-1848.4%–
Q2 FY2017Jun 30, 2017-5355.0%–

More Gyre Therapeutics figures

See a number that looks wrong?